Belite Bio (BLTE) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

-$0.70

Estimate

-$0.78

Surprise

+9.9%

Score today

5.5/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Belite Bio (BLTE) reported a narrower loss than forecast — diluted EPS of -$0.70 against the -$0.78 estimate (a 9.9% beat on a still-unprofitable quarter).

• Morgan Stanley Maintains Overweight on Belite Bio, Raises Price Target to $206 — benzinga, 2026-08-14
• Cantor Fitzgerald Maintains Overweight on Belite Bio, Raises Price Target to $270 — benzinga, 2026-08-14
• Full Transcript: Belite Bio Q2 2026 Earnings Call — benzinga, 2026-08-13

TrendMatrix currently rates BLTE Sell at 5.5/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's +9.9% surprise compares with a -14.7% four-quarter average. Next scheduled report: 2026-11-09.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$171.09

Price target

$186.18

Stop

$159.11

Upside to target

+8.8%

Reward-to-risk

0.7:1

Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$6.47B

P/E (fwd)

75.0

52-week range

$63.51–$200.00

Off 52-week high

14.5%

RSI (14)

58

Volume vs avg

1.17×

Score today

5.5/10